The KEYNOTE-028 trial which involved a cohort of people with existing colon and rectum carcinomas found only a 4% ORR for pembrolizumab monotherapy after screening out patients with PD-L1 > 1% (n = 1), and there was no significant improvement when compared with that of unscreened patients [132]. Here, CD274 is linked to digestive system neoplasm.